Yale University, School of Medicine, New Haven, CT, USA.
Department of Pathology, Yale Pathology Tissue Services, Yale University School of Medicine, 310 Cedar St. BML 116, PO Box 208023, New Haven, CT, 06520-8023, USA.
Breast Cancer Res. 2019 Jun 13;21(1):72. doi: 10.1186/s13058-019-1156-6.
The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associated with a better outcome. Two large studies have been done assessing immune cell PD-L1 expression in lung cancer. Here, we reanalyze one of those studies, to show that, even with an easier scoring method, there is still only poor agreement between assays and pathologist for immune cell PD-L1 expression.
用于检查点抑制剂免疫治疗的伴随诊断测试是一种 PD-L1 的免疫组织化学测试。该测试已被证明可在肿瘤细胞中进行重现性表达，但不能在免疫细胞中进行。在 IMpassion130 试验中使用了免疫细胞，该试验表明 PD-L1 表达与更好的结果相关。已经进行了两项大型研究来评估肺癌中的免疫细胞 PD-L1 表达。在这里，我们重新分析了其中一项研究，结果表明，即使使用更简单的评分方法，免疫细胞 PD-L1 表达在检测方法和病理学家之间仍然只有较差的一致性。
